Global Bioprocess Validation Market projected to reach USD 1380 million by 2033 with a CAGR of 14.48%.

From GlobeNewswire: 2024-06-28 02:00:00

The Global Bioprocess Validation Market is projected to grow from USD 357 million in 2023 to USD 1380 million by 2033, with a CAGR of 14.48%. Bioprocess validation ensures compliance with FDA guidelines to guarantee the safety, sustainability, and efficacy of biopharmaceutical products. The market is driven by the demand for outsourcing services to meet regulatory criteria in healthcare. The extractable and leachable testing segment dominates the market, with a focus on identifying potentially hazardous substances. The filter elements segment is expected to grow rapidly, ensuring product quality and integrity. Pharmaceutical companies lead the market, conducting research and developing drugs. Asia Pacific is expected to hold the largest market share, driven by rising healthcare costs and government investments. North America is predicted to grow rapidly due to outsourcing services and increased biologics production. Key players include Eurofins Scientific, Thermo Fisher Scientific, and others. In a recent development, Thermo Fisher Scientific and Moderna signed a 15-year strategic collaboration for large-scale production of Moderna’s COVID-19 vaccine and mRNA treatments. The market is segmented by test type, process component, end user, and region, providing forecasts until 2033.



Read more at GlobeNewswire: Global Bioprocess Validation Market Size To Worth USD 1380